EIF2A and prostate carcinoma: Consistent with these discoveries, we further confirmed that treatment of VCaP, LNCaP95 and 22Rv1 prostate cancer cells with NXP800, but not the inactive chemical control CCT365248, increased eIF2α phosphorylation and ATF4, ATF6, and IRE1 protein expression.